VASCULAR DISEASE: Vorapaxar prevents progression of peripheral artery disease

    loading  Checking for direct PDF access through Ovid

Abstract

The primary goals of antiplatelet therapy in peripheral artery disease are the prevention of cardiovascular ischaemic events and maintenance of revascularization patency. Vorapaxar is a novel agent that has a demonstrated clinical benefit in a broad population of patients, and also decreases the progression of limb ischaemia.

Related Topics

    loading  Loading Related Articles